GenSpera G-202 data in journal
The study published in Science Translational Medicine documents pre-clinical data and rationale for developing G-202 as a potential cancer therapy. G-202, combined with prodrug delivery, is effective at killing fast- and slow-growing cancers by targeting PSMA enzyme.